Biohaven (BHVN) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $10.78, -5.69% vs the prior close of $11.43.
- Volume 2.42M shares, 0.9x its 50-day average.
- New SEC filings: 8-K (Oct 15, 2026).
- No new insider buys or sales reported since the prior session.
BHVN slides 5.7% to $10.78, a 3-month low. Closed at $10.78, -5.69% vs the prior close of $11.43. Day range $10.71–$11.40, opened at $11.31.
BHVN daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — BHVN slides 5.7% to $10.78, a 3-month low
- Closed at $10.78, -5.69% vs the prior close of $11.43. Day range $10.71–$11.40, opened at $11.31.
- Volume was 2.42M shares, 0.9x its 50-day average of 2.82M.
- Price is -21.2% vs its 50-day average ($13.68) and -10.7% vs its 200-day average ($12.07).
- 52-week range $7.48–$18.57; today's close sits at 30% of that range, 41.9% below the 52-week high.
Oct 15, 2026 — BHVN jumps 4.6% to $11.43
- Closed at $11.43, +4.57% vs the prior close of $10.93. Day range $10.94–$11.66, opened at $10.95.
- Volume was 1.45M shares, 0.5x its 50-day average of 2.82M — lighter than usual.
- Price is -16.9% vs its 50-day average ($13.75) and -5.4% vs its 200-day average ($12.08).
- 52-week range $7.48–$18.57; today's close sits at 36% of that range, 38.4% below the 52-week high.
- SEC filings that day: 8-K.
Oct 14, 2026 — BHVN slides 4.3% to $10.93, a 3-month low, 3 down days in a row
- Closed at $10.93, -4.29% vs the prior close of $11.42. Day range $10.82–$11.50, opened at $11.39.
- Volume was 1.78M shares, 0.6x its 50-day average of 2.83M.
- Price is -20.8% vs its 50-day average ($13.79) and -9.5% vs its 200-day average ($12.08).
- 52-week range $7.48–$18.57; today's close sits at 31% of that range, 41.1% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — BHVN slides 3.3% to $11.42, a 3-month low
- Closed at $11.42, -3.30% vs the prior close of $11.81. Day range $11.16–$11.79, opened at $11.79.
- Volume was 2.43M shares, 0.9x its 50-day average of 2.81M.
- Price is -17.5% vs its 50-day average ($13.85) and -5.5% vs its 200-day average ($12.08).
- 52-week range $7.48–$18.57; today's close sits at 36% of that range, 38.5% below the 52-week high.
Oct 12, 2026 — BHVN dips 2.2% to $11.81, a 3-month low
- Closed at $11.81, -2.24% vs the prior close of $12.08. Day range $11.65–$11.99, opened at $11.91.
- Volume was 1.62M shares, 0.6x its 50-day average of 2.81M — lighter than usual.
- Price is -15.0% vs its 50-day average ($13.89) and -2.2% vs its 200-day average ($12.08).
- 52-week range $7.48–$18.57; today's close sits at 39% of that range, 36.4% below the 52-week high.
Oct 9, 2026 — BHVN rises 1.3% to $12.08
- Closed at $12.08, +1.26% vs the prior close of $11.93. Day range $11.74–$12.27, opened at $11.90.
- Volume was 1.37M shares, 0.5x its 50-day average of 2.81M — lighter than usual.
- Price is -13.2% vs its 50-day average ($13.92) and +0.1% vs its 200-day average ($12.07).
- 52-week range $7.48–$18.57; today's close sits at 41% of that range, 34.9% below the 52-week high.
Oct 8, 2026 — BHVN rises 0.4% to $11.93
- Closed at $11.93, +0.42% vs the prior close of $11.88. Day range $11.46–$12.12, opened at $11.83.
- Volume was 2.70M shares, 1.0x its 50-day average of 2.78M.
- Price is -14.5% vs its 50-day average ($13.96) and -1.1% vs its 200-day average ($12.07).
- 52-week range $7.48–$18.57; today's close sits at 40% of that range, 35.7% below the 52-week high.
Oct 7, 2026 — BHVN dips 1.7% to $11.88, a 3-month low
- Closed at $11.88, -1.66% vs the prior close of $12.08. Day range $11.85–$12.23, opened at $11.86.
- Volume was 2.15M shares, 0.8x its 50-day average of 2.81M.
- Price is -15.1% vs its 50-day average ($13.99) and -1.5% vs its 200-day average ($12.06).
- 52-week range $7.48–$18.57; today's close sits at 40% of that range, 36.0% below the 52-week high.
Oct 6, 2026 — BHVN slides 6.9% to $12.08
- Closed at $12.08, -6.86% vs the prior close of $12.97. Day range $11.88–$13.04, opened at $13.00.
- Volume was 3.05M shares, 1.1x its 50-day average of 2.79M.
- Price is -13.9% vs its 50-day average ($14.02) and +0.2% vs its 200-day average ($12.06).
- 52-week range $7.48–$18.57; today's close sits at 41% of that range, 34.9% below the 52-week high.
Oct 5, 2026 — BHVN rises 0.8% to $12.97
- Closed at $12.97, +0.78% vs the prior close of $12.87. Day range $12.45–$13.31, opened at $12.85.
- Volume was 1.67M shares, 0.6x its 50-day average of 2.79M — lighter than usual.
- Price is -7.8% vs its 50-day average ($14.07) and +7.6% vs its 200-day average ($12.05).
- 52-week range $7.48–$18.57; today's close sits at 50% of that range, 30.1% below the 52-week high.
Oct 2, 2026 — BHVN dips 2.1% to $12.87
- Closed at $12.87, -2.05% vs the prior close of $13.14. Day range $12.63–$13.51, opened at $13.41.
- Volume was 1.74M shares, 0.6x its 50-day average of 2.79M.
- Price is -8.7% vs its 50-day average ($14.10) and +6.9% vs its 200-day average ($12.04).
- 52-week range $7.48–$18.57; today's close sits at 49% of that range, 30.7% below the 52-week high.
BHVN latest news & SEC filings
Every SEC filing by or about BHVN in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 15, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Sep 17, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 10, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Aug 26, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Aug 14, 2026 · Form 3 — New insider holdings
Initial insider ownership statement (Form 3) — a new director, officer or 10% owner disclosed their holdings
Aug 14, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 10, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Aug 10, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$137.31M (prior year -$198.15M) (loss narrowed vs Jun 30, 2025)
- Diluted EPS: -$0.91 (prior year -$1.94) (loss narrowed vs Jun 30, 2025)
Aug 7, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
Jul 17, 2026 · Form 3 — New insider holdings
Initial insider ownership statement (Form 3) — a new director, officer or 10% owner disclosed their holdings
Jul 9, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
Jul 8, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Things to know before you trade BHVN
- Last results release: Aug 10, 2026 (8-K Item 2.02). Previous ones: May 4, 2026, Mar 2, 2026, Nov 10, 2025. Based on that rhythm, the next report is likely around Nov 9, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 2.96% (largest 7.9%).
- Liquidity: about 2.10M shares (≈$22.62M) trade per day on average.
- 52-week position: $10.78 vs a range of $7.48–$18.57 (30% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 24 open-market buys, 0 sales; latest: George C. Clark bought 17,000 shares on Nov 17, 2025.
- Latest filings: 8-K Oct 15, 2026; 8-K Sep 10, 2026; 8-K Aug 26, 2026.
- Share count: 151.04M shares outstanding (Aug 6, 2026), +42.8% vs a year earlier — notable dilution.
- Listing: NYSE · industry: Pharmaceutical Preparations.
BHVN market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 11.31 | 11.40 | 10.71 | 10.78 | 2.42M |
| Oct 15, 2026 | 10.95 | 11.66 | 10.94 | 11.43 | 1.45M |
| Oct 14, 2026 | 11.39 | 11.50 | 10.82 | 10.93 | 1.78M |
| Oct 13, 2026 | 11.79 | 11.79 | 11.16 | 11.42 | 2.43M |
| Oct 12, 2026 | 11.91 | 11.99 | 11.65 | 11.81 | 1.62M |
| Oct 9, 2026 | 11.90 | 12.27 | 11.74 | 12.08 | 1.37M |
| Oct 8, 2026 | 11.83 | 12.12 | 11.46 | 11.93 | 2.70M |
| Oct 7, 2026 | 11.86 | 12.23 | 11.85 | 11.88 | 2.15M |
| Oct 6, 2026 | 13.00 | 13.04 | 11.88 | 12.08 | 3.05M |
| Oct 5, 2026 | 12.85 | 13.31 | 12.45 | 12.97 | 1.67M |
| Oct 2, 2026 | 13.41 | 13.51 | 12.63 | 12.87 | 1.74M |
| Oct 1, 2026 | 13.31 | 13.62 | 13.03 | 13.14 | 1.51M |
| Sep 30, 2026 | 13.50 | 13.62 | 13.21 | 13.35 | 1.43M |
| Sep 29, 2026 | 13.12 | 13.50 | 12.93 | 13.29 | 1.53M |
| Sep 28, 2026 | 12.82 | 13.42 | 12.49 | 13.27 | 2.05M |
| Sep 25, 2026 | 13.25 | 13.35 | 12.77 | 12.99 | 1.58M |
| Sep 24, 2026 | 13.43 | 13.63 | 12.76 | 13.19 | 3.03M |
| Sep 23, 2026 | 14.84 | 14.84 | 13.51 | 13.67 | 2.74M |
| Sep 22, 2026 | 14.42 | 14.97 | 14.22 | 14.85 | 2.43M |
| Sep 21, 2026 | 13.90 | 14.49 | 13.56 | 14.22 | 3.29M |
About Biohaven
Biohaven (BHVN) is listed on the NYSE and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in NEW HAVEN, CT. State of incorporation: Virgin Islands, British. Fiscal year ends December 31. SEC CIK 1935979.
BHVN board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Irina Antonijevic | Director | Apr 30, 2026 |
| Gregory Bailey | Director | Apr 30, 2026 |
| John W Childs | Director | Apr 30, 2026 |
| Vlad Coric | Chief Executive Officer | Mar 3, 2026 |
| Julia P Gregory | Director | Apr 30, 2026 |
| Robert J Hugin | Director | Apr 30, 2026 |
| Michael Thomas Heffernan | Director | Apr 30, 2026 |
| Kishan Mehta | Director | Apr 30, 2026 |
| John Yetimoglu | Director | Aug 14, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Matthew Buten | Chief Financial Officer | Mar 3, 2026 |
| Bruce Car | Chief Scientific Officer | Mar 3, 2026 |
| George C. Clark | VP, Chief Accounting Officer | Mar 3, 2026 |
| Vlad Coric | Chief Executive Officer | Mar 3, 2026 |
| Kimberly Gentile | SVP, Clinical Operations | Sep 17, 2026 |
| Warren Karl Volles | Chief Legal Officer | Jul 17, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Nov 17, 2025 | George C. Clark | Buy | 17,000 | $8.52 |
| Nov 17, 2025 | George C. Clark | Buy | 17,000 | $8.52 |
| Nov 17, 2025 | George C. Clark | Buy | 17,000 | $8.52 |
| Nov 17, 2025 | George C. Clark | Buy | 17,000 | $8.52 |
| Nov 13, 2025 | Gregory Bailey | Buy | 400,000 | $7.50 |
| Nov 13, 2025 | Gregory Bailey | Buy | 400,000 | $7.50 |
| Nov 13, 2025 | Gregory Bailey | Buy | 400,000 | $7.50 |
| Nov 13, 2025 | Gregory Bailey | Buy | 400,000 | $7.50 |
| Nov 13, 2025 | John W Childs | Buy | 3,333,333 | $7.50 |
| Nov 13, 2025 | John W Childs | Buy | 3,333,333 | $7.50 |
| Nov 13, 2025 | John W Childs | Buy | 3,333,333 | $7.50 |
| Nov 13, 2025 | John W Childs | Buy | 3,333,333 | $7.50 |
| Nov 13, 2025 | Vlad Coric | Buy | 333,333 | $7.50 |
| Nov 13, 2025 | Vlad Coric | Buy | 333,333 | $7.50 |
| Nov 13, 2025 | Vlad Coric | Buy | 333,333 | $7.50 |
BHVN financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-738.82M | -6.86 | $-609.44M |
| Dec 31, 2024 | — | $-846.42M | -9.28 | $-582.45M |
| Dec 31, 2023 | — | $-408.17M | -5.73 | $-331.73M |
| Dec 31, 2022 | — | $-570.28M | -12.75 | $-297.69M |
| Dec 31, 2021 | — | $-213.80M | -5.43 | $-145.84M |
Latest balance sheet: total assets $370.74M, total liabilities $358.52M, cash $238.03M (as of Jun 30, 2026).
BHVN earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 10, 2026 | 8-K Item 2.02 (results) | $14.54 |
| May 4, 2026 | 8-K Item 2.02 (results) | $10.14 |
| Mar 2, 2026 | 8-K Item 2.02 (results) | $11.81 |
| Nov 10, 2025 | 8-K Item 2.02 (results) | $7.79 |
| Aug 11, 2025 | 8-K Item 2.02 (results) | $13.41 |
| May 12, 2025 | 8-K Item 2.02 (results) | $20.56 |
| Mar 3, 2025 | 8-K Item 2.02 (results) | $32.06 |
| Nov 12, 2024 | 8-K Item 2.02 (results) | $50.36 |
| Aug 8, 2024 | 8-K Item 2.02 (results) | — |
| May 9, 2024 | 8-K Item 2.02 (results) | — |
| Feb 29, 2024 | 8-K Item 2.02 (results) | — |
| Nov 14, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on BHVN
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.